Sanofi Stock News

French healthcare company Sanofi has agreed to buy the drug development project INBRX-101 from its parent company Inhibrx Inc for around $2.2 billion, the companies said on Tuesday.

Senior U.S. officials met this week with the manufacturers of RSV immunizations for infants, pushing companies including Sanofi and AstraZeneca to continue efforts to meet demand, the White House said

Sanofi is hoping that by sponsoring the Olympic Games it can attract new talent, reward existing staff and shake off the French drugmaker's conservative image.

Sanofi (SNY) Presents at J.P. Morgan 42nd Annual Healthcare Conference Call Transcript

The Pharmaceutical segment offers human health pharmaceutical products in: Oncology, Hospital acute care Immunology Neuroscience Virology Cardiovascular and diabetes Vaccine products, such as preventi

AstraZeneca and Sanofi's respiratory syncytial virus (RSV) immunization for infants has been approved in China, the London-listed drugmaker said on Tuesday.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

With so many innovative firms skyrocketing this year, astute investors seeking compelling discounts may want to turn their attention to undervalued biotech picks. Just like advancements in the digital

The Federal Trade Commission has been scrutinizing Big Pharma deals, finally scoring a win with Sanofi (SNY) scrapping its proposed licensing deal with Maze Therapeutics. The FTC said it would seek to

Sanofi SA SAN, +1.94% said late Monday it will scuttle an agreement with biotech Maze Therapeutics Inc. after federal trade regulators sought to block it, saying the deal would eliminate competition f

Sanofi said on Monday it was terminating a deal to exclusively license a drug that Maze Therapeutics is developing to treat Pompe disease because of objections from the U.S. government.

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

Sanofi (SNY) aims to generate annual sales of over 10 billion euros by 2030, driven by recently launched and potential new products. It intends to enhance R&D focus to become a market leader in immuno

Sanofi said it would spend close to 700 million euros ($754 million) more on drugs development next year, specifying for the first time an increase in costs that roiled investors and triggered a sell-

Sanofi said on Thursday it will focus on 12 potential blockbuster drug candidates and prioritise development in immunology, as it faces investor pressure after abandoning 2025 margin targets while boo